We further noted that mutations targeting TBX3 were confined to EA patients and those targeting the FBXW7 tumor suppressor to AA patients whereas mutations in the ARID1A gene were distinctively enriched among Kenyan patients. The gene discussed is ARID1A; the disease is neoplasm.